We are live on ! Find out more
AKTX

Akari Therapeutics
AKTX

13 hedge funds and large institutions have $4.15M invested in Akari Therapeutics in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

30% more funds holding

Funds holding: 10 → 13 (+3)

12% more capital invested

Capital invested by funds: $3.7M → $4.15M (+$447K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OFW
Omnia Family Wealth
Florida
+$313K
2
Renaissance Technologies
Renaissance Technologies
New York
+$66.3K
3
HighTower Advisors
HighTower Advisors
Illinois
+$38.3K
4
TSS
Two Sigma Securities
New York
+$23.6K
5
Envestnet Asset Management
Envestnet Asset Management
Illinois
+$19.2K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$53K
2
ARTA
A.R.T. Advisors
New York
-$36K
3
TC
Truvestments Capital
Florida
-$6K
4
UBS Group
UBS Group
Switzerland
-$4K
5
Morgan Stanley
Morgan Stanley
New York
-$1.47K
Name Holding Trade Value Shares
Change 		Change in
Stake
HP
1
Hikari Power
Japan
$2.63M – – –
NMC
2
NEA Management Company
Maryland
$791K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$301K +$66.3K +45 +26%
OFW
4
Omnia Family Wealth
Florida
$297K +$313K +212 New
HighTower Advisors
5
HighTower Advisors
Illinois
$64K +$38.3K +26 +137%
TSS
6
Two Sigma Securities
New York
$22K +$23.6K +16 New
Envestnet Asset Management
7
Envestnet Asset Management
Illinois
$18K +$19.2K +13 New
OAM
8
Oxford Asset Management
United Kingdom
$18K +$19.2K +13 New
Bank of America
9
Bank of America
North Carolina
$5K – – –
Morgan Stanley
10
Morgan Stanley
New York
$2K -$1.47K -1 -50%
AG
11
Advisor Group
Arizona
$2K +$1.47K +1 New
PCG
12
Private Capital Group
Connecticut
$2K +$2.95K +2 New
Deutsche Bank
13
Deutsche Bank
Germany
$1K +$1.47K +1 New
VF
14
Virtu Financial
New York
– -$53K -39 Closed
ARTA
15
A.R.T. Advisors
New York
– -$36K -27 Closed
TC
16
Truvestments Capital
Florida
– -$6K -5 Closed
UBS Group
17
UBS Group
Switzerland
– -$4K -3 Closed

AKTX Hedge Fund Activity: Q4 2019 in Review

13 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q4 2019, worth a combined $4.15M — up 12% from $3.7M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AKTX positions and 4 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Omnia Family Wealth, opening a new position worth an estimated $313K. The largest seller was Virtu Financial, exiting entirely with an estimated $53K sold.

  • 13 institutional investors held Akari Therapeutics (AKTX) as of Q4 2019, up from 10 in Q3 2019.
  • Funds reported $4.15M of Akari Therapeutics stock for Q4 2019, up 12% quarter-over-quarter.
  • 7 funds opened new Akari Therapeutics positions in Q4 2019 and 4 closed out, a net change of +3 holders.
  • The largest Akari Therapeutics buyer in Q4 2019 was Omnia Family Wealth, an estimated $313K added.
  • The largest Akari Therapeutics seller in Q4 2019 was Virtu Financial, an estimated $53K sold.

Based on aggregated 13F filings for Q4 2019.